Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Marina Blagodatny

Geriatric Medicine Stratford, CT Medical Doctor

NPI 1447291497 CMS profile 246910

95 Armory Rd, Stratford, CT 06614

Open in the dashboard

General payments

$3,363

35 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Marina Blagodatny of Stratford, CT is reported in the CMS Open Payments database as having received $3,363 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $2 1
2022 General $74 1
2021 General $320 3
2020 General $617 7
2019 General $2,351 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marina Blagodatny
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Marina Blagodatny were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Marina Blagodatny Geriatric Medicine median Middle half National median
2019 $2,351 $122 $40–$435 $163
2020 $617 $98 $25–$349 $114
2021 $320 $125 $34–$441 $132
2022 $74 $124 $36–$408 $149
2023 $2 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $0 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $494 4 payments
  2. Allergan Inc. $395 3 payments
  3. Janssen Pharmaceuticals, Inc $332 4 payments
  4. AbbVie, Inc. $315 3 payments
  5. Merck Sharp & Dohme Corporation $216 2 payments
  6. Teva Pharmaceuticals USA, Inc. $199 2 payments
  7. Akcea Therapeutics, Inc. $160 2 payments
  8. Amarin Pharma Inc. $131 2 payments
  9. Otsuka America Pharmaceutical, Inc. $125 1 payment
  10. Astellas Pharma US Inc $125 1 payment
  11. Other $872 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,357 34 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2023
  1. VRAYLAR $395 3 payments
  2. XARELTO $332 4 payments
  3. Repatha $244 2 payments
  4. STEGLATRO $216 2 payments
  5. AUSTEDO $199 2 payments
  6. TEGSEDI $160 2 payments
  7. Vascepa $131 2 payments
  8. ABILIFY MAINTENA $125 1 payment
  9. MYRBETRIQ $125 1 payment
  10. EVENITY $125 1 payment
  11. Other $1,496 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

5,097

Median for Geriatric Medicine: 2,306

Drug cost

$441,424

Median for Geriatric Medicine: $150,713

Branded share of claims

17.6%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 22 $153,287
Eliquis Apixaban Brand 186 $77,309
Xarelto Rivaroxaban Brand 79 $29,779
Tradjenta Linagliptin Brand 53 $18,265
Jardiance Empagliflozin Brand 40 $17,806
Januvia Sitagliptin Phosphate Brand 37 $11,125
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $10,046
Divalproex Sodium Generic 87 $9,285
Myrbetriq Mirabegron Brand 19 $8,775
Trazodone Hcl Generic 485 $7,385

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$71,670

Medicare's payments for the services billed

Medicare patients

246

Average age 84

Services billed

725

164 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Alzheimer's or dementia 58%
Depression 53%
Ischemic heart disease 47%
Heart failure 45%
Chronic kidney disease 42%
Diabetes 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record